CD8A and neoplasm: Research has confirmed that IL-36β can promote the activation of CD8+ T cells by activating mTORC1 through PI3K/Akt, IKK, and MyD88 pathways, thereby enhancing the anti-tumor immune response and laying the groundwork for the application of IL-36β in tumor immunotherapy (18).